Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease

被引：2

作者：

Bourdin, V. ^{[1
,9
]}

Fosse, Q. ^{[2
]}

Lambotte, O. ^{[1
,3
]}

Joly, B. ^{[4
,5
,6
]}

Coppo, P. ^{[6
,7
]}

Anguel, N. ^{[2
]}

Labeyrie, C. ^{[8
]}

机构：

[1] Univ Paris Saclay, Hop Bicetre, AP HP, Internal Med Dept, Le Kremlin Bicetre, France

[2] Univ Paris Saclay, Hop Bicetre, AP HP, FHU SEPSIS,Intens Care Unit.DMU CORREVE,Grp Rech C, Le Kremlin Bicetre, France

[3] Univ Paris Saclay, Inserm, CEA, UMR ImVA HB 1184, Le Kremlin Bicetre, France

[4] Hop Lariboisiere, Biol Hematol Dept, Paris, France

[5] Univ Paris Cite, AP HP Nord, Inst Rech St Louis, EA3518, Paris, France

[6] Sorbonne Univ, St Antoine Univ Hosp, AP HP, French Reference Ctr Thrombot Microangiopathies CN, Paris, France

[7] Sorbonne Univ, Hop St Antoine, AP HP, Hematol Dept, Paris, France

[8] Univ Paris Saclay, Hop Bicetre, AP HP, Dept Neurol, Le Kremlin Bicetre, France

[9] Hop Bicetre, Serv Med Interne, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 04期

关键词：

autoimmune disease; drug antibodies; TTP;

D O I：

10.1111/bjh.19263

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening disease that may result from drug exposure. We report a case of iTTP occurring in a 39-year-old patient, 45 months following introduction of the anti-CD52 lymphoid cell depleting monoclonal antibody alemtuzumab, to treat a relapsing-remitting multiple sclerosis. Treatment consisted in plasma exchange, corticosteroids and caplacizumab, allowing clinical remission 3 months after the diagnosis, attested by the absence of thrombocytopenia and recovery of ADAMTS-13 activity. As other autoimmune disorders, iTTP may occur following alemtuzumab. This diagnosis should be suspected in patients with features of thrombotic microangiopathy following this treatment.

引用

页码：1459 / 1463

页数：5

共 15 条

[1] Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab [J].

Baker, David ;

Herrod, Samuel S. ;

Alvarez-Gonzalez, Cesar ;

Giovannoni, Gavin ;

Schmierer, Klaus .

JAMA NEUROLOGY, 2017, 74 (08) :961-969

[2] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

[3] Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management [J].

Cuker, Adam ;

Bass, Ann D. ;

Nadj, Congor ;

Agius, Mark A. ;

Steingo, Brian ;

Selmaj, Krzysztof W. ;

Thoits, Timothy ;

Guerreiro, Alexandre ;

Van Wijmeersch, Bart ;

Ziemssen, Tjalf ;

Meuth, Sven G. ;

LaGanke, Christopher C. ;

Thangavelu, Karthinathan ;

Rodriguez, Claudio E. ;

Baker, Darren P. ;

Margolin, David H. ;

Jannsens, Ann .

MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (01) :48-56

[4] Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis [J].

Daniels, Gilbert H. ;

Vladic, Anton ;

Brinar, Vesna ;

Zavalishin, Igor ;

Valente, William ;

Oyuela, Pedro ;

Palmer, Jeffrey ;

Margolin, David H. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (01) :80-89

[5] Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion [J].

Dunn, Alanna ;

Lam, Anna ;

Hidalgo, Luis ;

Shapiro, A. M. James ;

Senior, Peter A. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (04) :1141-1147

[6] Thrombotic thrombocytopenic purpura [J].

Hovinga, Johanna A. Kremer ;

Coppo, Paul ;

Laemmle, Bernhard ;

Moake, Joel L. ;

Miyata, Toshiyuki ;

Vanhoorelbeke, Karen .

NATURE REVIEWS DISEASE PRIMERS, 2017, 3

[7] Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study [J].

Keating, MJ ;

Flinn, I ;

Jain, V ;

Binet, JL ;

Hillmen, P ;

Byrd, J ;

Albitar, M ;

Brettman, L ;

Santabarbara, P ;

Wacker, B ;

Rai, KR .

BLOOD, 2002, 99 (10) :3554-3561

[8] Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis [J].

Li, Z. ;

Richards, S. ;

Surks, H. K. ;

Jacobs, A. ;

Panzara, M. A. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 194 (03) :295-314

[9] Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration or Alemtuzumab: A Case Report [J].

Liou, Ashley A. ;

Skiver, Brent M. ;

Yates, Eric ;

Persad, Paul ;

Meyer, David ;

Farland, Andrew M. ;

Rocco, Michael V. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (05) :615-619

[10] Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre [J].

Manso, Jacopo ;

Zhu, Yi Hang ;

Margoni, Monica ;

Rinaldi, Francesca ;

Censi, Simona ;

Carducci, Sofia ;

Cosma, Chiara ;

Plebani, Mario ;

Gallo, Paolo ;

Mian, Caterina .

CLINICAL ENDOCRINOLOGY, 2022, 97 (03) :331-338

← 1 2 →